Skip to main content
logo
Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
10.97
+0.03 (0.27%)
Oct 19, 2026, 10:55 AM EDT - Market open

Sutro Biopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
45.7102.4862.04153.7367.7761.88
Revenue Growth
-56.26%65.18%-59.64%126.84%9.52%44.84%
Gross Profit
-99.04-63.93-190-26.69-69.4-42.52
Operating Income
-131.86-104.95-238.45-89.28-128.94-98.52
Net Income
-180.64-191.09-227.46-106.79-119.2-105.54
Earnings Per Share
-15.47-22.49-29.40-17.75-23.49-22.88
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
164.35141.43316.9375.62334.36266.71
Total Debt
10.7815.6723.1533.6450.4357.37
Net Cash (Debt)
153.56125.75293.74341.98283.93209.34
Net Cash Growth
-17.23%-57.19%-14.11%20.45%35.63%-39.07%
Net Cash Per Share
13.1514.8037.9756.8455.9645.39

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-145.17-177.23-191.54-111.623.55-81.68
Capital Expenditures
-0.45-1.7-3.1-4.32-7.86-15.32
Free Cash Flow
-145.62-178.93-194.64-115.93-4.31-97
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-216.71%-62.38%--17.36%-102.40%-68.71%
Operating Margin
-288.52%-102.41%-384.33%-58.07%-190.26%-159.22%
Pretax Margin
-395.46%-186.55%-362.81%-57.63%-172.20%-170.55%
Profit Margin
-395.25%-186.45%-366.62%-69.47%-175.89%-170.55%
FCF Margin
-318.63%-174.59%-313.72%-75.41%-6.36%-156.76%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.970.962.441.706.8511.13